Studies have shown that GPC5 expression was lower in tumors with a relatively better prognosis, while it was higher in tumors with greater metastatic potential, such as in small cell lung cancer and rhabdomyosarcoma (6–9). The gene discussed is GPC5; the disease is rhabdomyosarcoma.